Myelodysplastic Syndrome (MDS)
We recommend
Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia,…
How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells…
Articles on this topic
Treatment of Low-Risk MDS According to NCCN Recommendations Version 1.2023
The latest recommendations from the American National Comprehensive Cancer Network (NCCN) for…
ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome
The priority in the treatment of low-risk myelodysplastic syndrome (MDS) is managing…
Effect of Luspatercept Treatment in Patients with MDS/MPN-RS-T
The presented post hoc analysis of the MEDALIST study demonstrates the effect and good…
Diagnosing Myelodysplastic Syndrome According to MDS Europe
In 2021, the European Hematology Association (EHA) endorsed the recommendations of the MDS…
Subscribe
E-courses on this topic
Conferences news
Go to records
Most read on this topic
- Promising treatment modalities in the therapy of myelodysplastic syndromes
- How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
- Role of the transforming growth factor (TGF)-β signal pathway in haematopoiesis and studies of new inhibitors of this pathway in the treatment of lower-risk myelodysplastic syndrome
- ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome
- Treatment strategies for myelodysplastic syndrome in 2021
- Diagnosing Myelodysplastic Syndrome According to MDS Europe
Journal on this topic
Related topic